Abstract
Patients with ulcerative colitis uniformly have disease involving the distal colon. When patients have disease limited to the left colon or symptoms suggestive of active rectal inflammation, guidelines recommend topical rectal therapies as first-line agents either as monotherapy or in conjunction with oral products. Rectal delivery modalities offer the advantage of delivering high local concentrations of active medication to the site of maximal inflammation with minimization of systemic side effects. Methods of rectal administration include suppositories, liquid enemas and foams. Suppositories are limited to the treatment of rectal disease, and patients often have difficulty retaining the liquid enema secondary to its high volume and consistency. Rectal foams reliability extend to the descending and sigmoid colon with application. Foams are further characterized by increased viscosity, lower volumes, finer dispersion on the colonic mucosa, and increased adhesiveness to the colonic mucosa compared with liquid enemas. Additionally, rectal foam agents demonstrate equal efficacy to their liquid enema counterparts yet consistently yield better patient tolerance, lower incidence of side effects, and increased patient acceptability. Currently available agents include 5-aminosalicylic acid and corticosteroids, both first and newer generation. This review focuses on clinical trials assessing efficacy, tolerability, and patient preferences for these agents as well as describing the currently available rectal foam products.
Keywords: Ulcerative colitis, proctitis, enemas, foam preparations, 5-aminosalicylic acid, corticosteroids, systematic review
Current Drug Delivery
Title:Foam Preparations for the Treatment of Ulcerative Colitis
Volume: 9 Issue: 4
Author(s): Burr J. Loew and Corey A. Siegel
Affiliation:
Keywords: Ulcerative colitis, proctitis, enemas, foam preparations, 5-aminosalicylic acid, corticosteroids, systematic review
Abstract: Patients with ulcerative colitis uniformly have disease involving the distal colon. When patients have disease limited to the left colon or symptoms suggestive of active rectal inflammation, guidelines recommend topical rectal therapies as first-line agents either as monotherapy or in conjunction with oral products. Rectal delivery modalities offer the advantage of delivering high local concentrations of active medication to the site of maximal inflammation with minimization of systemic side effects. Methods of rectal administration include suppositories, liquid enemas and foams. Suppositories are limited to the treatment of rectal disease, and patients often have difficulty retaining the liquid enema secondary to its high volume and consistency. Rectal foams reliability extend to the descending and sigmoid colon with application. Foams are further characterized by increased viscosity, lower volumes, finer dispersion on the colonic mucosa, and increased adhesiveness to the colonic mucosa compared with liquid enemas. Additionally, rectal foam agents demonstrate equal efficacy to their liquid enema counterparts yet consistently yield better patient tolerance, lower incidence of side effects, and increased patient acceptability. Currently available agents include 5-aminosalicylic acid and corticosteroids, both first and newer generation. This review focuses on clinical trials assessing efficacy, tolerability, and patient preferences for these agents as well as describing the currently available rectal foam products.
Export Options
About this article
Cite this article as:
J. Loew Burr and A. Siegel Corey, Foam Preparations for the Treatment of Ulcerative Colitis, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323062
DOI https://dx.doi.org/10.2174/156720112801323062 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate
Recent Patents on Inflammation & Allergy Drug Discovery Growth Hormone/Insulin-Like Growth Factor-I Axis and Insulin in Alzheimers Disease and Its Possible Treatment Usefulness
Central Nervous System Agents in Medicinal Chemistry Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
CNS & Neurological Disorders - Drug Targets Hypothalamic Leptin and Ghrelin Signaling as Targets for Improvement in Metabolic Control
Current Pharmaceutical Design The CNS Melanocortin System: A Biological Weapon Against the Threat of Obesity
Current Medicinal Chemistry - Central Nervous System Agents Is the Cerebellum Involved in the Nervous Control of the Immune System Function?
Endocrine, Metabolic & Immune Disorders - Drug Targets New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Neurohypophyseal Dysfunction During Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular and Genetic Mechanisms of Obesity: Implications for Future Management
Current Molecular Medicine Prevalence of Diabetes Among Immigrants in the Nordic Countries
Current Diabetes Reviews Molecular and Genetic Mechanisms of Osteoporosis: Implication for Treatment
Current Molecular Medicine Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Current Drug Targets AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design